News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kalypsys, Inc. On Track To Complete Phase Ia Study for Drug Candidate, KD3010, For Metabolic Disorders By End Of October



9/26/2006 11:18:09 AM

SAN DIEGO--(BUSINESS WIRE)--Kalypsys Inc. announced today that it has initiated and expects to complete a Phase Ia clinical trial of KD3010, a small molecule Peroxisome Proliferator-Activator Receptor Delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity, by the end of October.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES